Skip to content

Join Us
Members Area

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Publication Category: Medications

The Future of Obesity Care: Exploring Synergies Between Metabolic Bariatric Surgery, Interventional Endoscopy and Pharmacotherapy

Brown WA, Sumithran P, Cowley M, Cohen R, Le Roux C, Schauer P, Agarwal S, Ard J, Boza C, Cargiuolo JL, Ceccarelli L, Coverdale J, Dunkin B, Finucane F, Gupta K, Kaplan LM, Kurian M, Lingvay I, Miras A, Pearlman C, Petry T, Pournaras D, Purnell J, Ruiz R, The Future of Obesity Care: Exploring Synergies Between Metabolic Bariatric Surgery, Interventional Endoscopy and Pharmacotherapy Obes Surg

Unimolecular GLP-1/Apelin Hybrid Peptides Cause Prominent Appetite Suppression, as Well as Enhancing Insulin Secretion, Beta-Cell Survival and Glycaemic Regulation

Sridhar A, Palmer ES, Craig SL, Krason-Kidzinska E, Irwin N, O'Harte FPM. Unimolecular GLP-1/Apelin Hybrid Peptides Cause Prominent Appetite Suppression, as Well as Enhancing Insulin Secretion, Beta-Cell Survival and Glycaemic Regulation Diabetes Obes Metab
Insulin Resistance & Diabetes

Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial

Horn DB, Aronne LJ, Wharton S, Bays HE, le Roux CW, Srinath R, Gomez-Valderas E, Arad AD, Das S, Dunn JP, Ribeiro A, Glass LC, Lee CJ. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial Lancet

Treatment of the disease of obesity in patients with type 1 diabetes with tirzepatide: a protocol for a randomised controlled trial in a single-centre setting

Al Ozairi E, Al Awadhi A, Taghadom E, Al Kandari J, Alsaeed D, Alghanim S, Mashankar A, Le Roux C. Treatment of the disease of obesity in patients with type 1 diabetes with tirzepatide: a protocol for a randomised controlled trial in a single-centre setting BMJ Open
Insulin Resistance & Diabetes

Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial

Aronne LJ, Horn DB, le Roux CW, Chao AM, Ho W, Halpern B, Griffin R, Xie C, Valderas EG, Lee CJ, Ribeiro A, Hyman DM, Glass L, Xavier N. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial Nat Med

Effects of Bariatric Surgery and Obesity Medicines on Human Eating Behavior

Contreras Hernández F, Villelabeitia I, Levine I, le Roux CW, Miras AD, Price RK. Effects of Bariatric Surgery and Obesity Medicines on Human Eating Behavior Annu Rev Nutr

Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial

Stanley C, Mallik R, Hamid N, Jassil FC, Reuven V, Ruwona T, Dicken SJ, Qamar S, Norton B, Kingett H, Pucci A, Magee C, Boniface D, Batterham RL, Devalia K, Mok J, Elkalaawy M, Loy J, Jenkinson A, Markakis H, Adamo M, Brown A, Makaronidis J. Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial Nat Med

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Thyroid Function Tests: A Systematic Review Identifying a Critical Evidence Gap

Salama S, Elfaki Omer EO, Mahmoud A, Mohamed ElshikhIdris MA, Mahadi Hussien TM, Ahmed M, Fadulelsayed SO, Mohammed Ibrahim SA, Ali Mohammed HO, Alhajri AHM. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Thyroid Function Tests: A Systematic Review Identifying a Critical Evidence Gap Int J Cardiol

Efficacy and Safety of Tranexamic Acid Use in Bariatric Surgery: An Updated Systematic Review and Meta-Analysis

Park LJ, Polley H, Poole M, Brar K, McKechnie T, Nenshi R, Borges FK, Ofori S, Marcucci M, Conen D, Lee Y, Anvari M, Eskicioglu C, Hong D, Devereaux PJ. Efficacy and Safety of Tranexamic Acid Use in Bariatric Surgery: An Updated Systematic Review and Meta-Analysis Obes Surg

Targeting Multiple Gut-Brain Pathways in Obesity: Rationale for Combination Pharmacotherapy

Miras AD, Hussain M. Targeting Multiple Gut-Brain Pathways in Obesity: Rationale for Combination Pharmacotherapy Obes Sci Pract
Gut-Brain

Older posts

Newer posts

← Previous Page1 Page2 Page3 … Page30 Next →

Search for:

Recent Posts

10th ASOI Annual Scientific Meeting 2026
9th ASOI Annual Conference – Registration now open!
Press Release for World Obesity Day 4th March 2024
ASOI and ICPO response to : Medical Council Communication: “Important medicine shortage information – Ozempic (semaglutide)”
Things to do in Dublin during ECO

ASOI

info@asoi.info

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Privacy Policy
Site Map

©2026 ASOI